Rosuvastatin-induced thrombocytopenic purpura - A case report

Dermatologica Sinica

Volumn 27, Issue 4, 2009, Pages 235-240

  Lin, Zheng Wei ^a   Ho, Hsin Chun ^a   Yang, Chih Hsun ^a   Hui, Rosaline Chung Yee ^a   Chung, Wen Hung ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

High density lipoprotein; Idiopathic thrombocytopenic purpura; Low density lipoprotein; Rosuvastatin; Thrombotic thrombocytopenic purpura

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; FENOFIBRATE; LOSARTAN; METHYLPREDNISOLONE; PROTEINASE ACTIVATED RECEPTOR 1; ROSUVASTATIN; THROMBIN RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD CELL COUNT; CAUCASIAN; CLINICAL ARTICLE; DRUG WITHDRAWAL; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; LABORATORY TEST; MALE; PETECHIA; PHYSICAL EXAMINATION; PURPURA; RACE DIFFERENCE; THROMBOCYTOPENIC PURPURA;

EID: 74549211282     PISSN: 10278117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. George JN, Raskob GE, Shah SR, et al.: Druginduced thrombocytopenia. A systematic review of published case reports. Ann Intern Med 129: 886-890, 1998.
2. Schuster H: Rosuvastatin - a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 99: 126-139, 2003.
3. Barbara A. Konkle: Disorders of the platelet and vessel wall. In: Handin RI, Fauci AS, Kasper DL , et al.: Harrison's Principles of Internal Medi cine. 17th ed. New York: McGraw Hill 719-725, 2008.
4. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 97: 105-116, 2002.
5. Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20: 303-328, 2002.
6. Lee E, Ryan S, Birmingham B, et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78: 330-341, 2005.
7. Y. Nishizato, I. Ieiri, H. Suzuki, et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73: 554-565, 2003.
8. McCarthy LJ, Porcu P, Fausel CA, et al.: Thrombotic thrombocytopenic purpura and simvastatin. Lancet 352: 1284-1285, 1998.
9. Groneberg DA, Barkhuizen A, Jeha T: Simvastatin-induced thrombocytopenia. Am J Hematol 67: 277, 2001.
10. González-Ponte ML, González-Ruiz M, Duvós, et al.: Atorvastatin-induced severe thrombocytopenia. Lancet 352: 1284, 1998.
11. F Sundram, P Roberts, B Kennedy, et al.: Thrombotic thrombocytopenic purpura associated with statin treatmemt. Postgrad Med J 80: 551-552, 2004.
12. Lijnen P, Echevaria-Vazquez D, Petrov V: Influence of cholesterol-lowering on plasma membrane lipids and function. Methods Find Exp Clin Pharmacol 18: 123-136, 1996.
13. Serebruany VL, Miller M, Pokov AN, et al.: Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97: 1332-1336, 2006.